Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
2/185 von 416    DIMDI: MEDLINE (ME60) © NLM
ND: ME12911236
PMID: 12911236
LR: 20041117
CED: 20030812
DCO: 20031009
Autoren: Hungerford MW; Valaik D
Titel: Chondroprotective agents: glucosamine and chondroitin.
Quelle: Foot and ankle clinics; VOL: 8 (2); p. 201-19 /200306/
PM: Print
SU: IM
Sprache: English
CY: United States
JID: 9615073
ISSN: 1083-7515
Institution: Johns Hopkins University, Suite G-1 Professional Office Building, 5601 Loch Raven Boulevard, Baltimore, MD 21239, USA. mhunger@Jhmi.edu
DT: Journal Article; Review
RN: 109
Schlagwörter
CT: BIOLOGICAL AVAILABILITY; CARTILAGE/anatomy & histology; CARTILAGE/physiology; CARTILAGE/physiopathology; CHONDROITIN/pharmacokinetics; CHONDROITIN/*therapeutic use; DRUG THERAPY, COMBINATION; GLUCOSAMINE/pharmacokinetics; GLUCOSAMINE/*therapeutic use; HUMANS; OSTEOARTHRITIS/*drug therapy; OSTEOARTHRITIS/metabolism
CTG: BIOLOGISCHE VERFÜGBARKEIT; KNORPEL/Anatomie & Histologie; KNORPEL/Physiologie; KNORPEL/Pathophysiologie; CHONDROITIN/Pharmakokinetik; CHONDROITIN/*therapeutische Anwendung; ARZNEIMITTEL-KOMBINATIONSTHERAPIE; GLUCOSAMIN/Pharmakokinetik; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; OSTEOARTHROSE/*Arzneimitteltherapie; OSTEOARTHROSE/Stoffwechsel
TE: Glucosamine/3416-24-8; Chondroitin/9007-27-6
CR: 3416-24-8; 9007-27-6
AB: The near universal finding of the safety of glucosamine and chondroitin combined with some compelling evidence of their efficacy should spur further research into their mechanism of action, optimal dosing, long-term effects on disease modification, and clinical applicability. When recommending a supplement to patients, the clinician should take into account the purity of the ingredients, reputation of the manufacturer, and the molecular weight of chondroitin supplied.
» Volltext »

» Fenster schließen »